ANVISA Event Details Changes in RDC 954/2024

On March 13, ANVISA held an exclusive event on RDC 954/2024, which brings important updates to the simplified registration of medicines. The high demand for face-to-face participation led to the opening of online transmission, allowing a greater number of professionals to follow the changes in real time.

QR Group, a reference in health product regulation, is attentive to the new guidelines and ready to assist pharmaceutical companies in adapting to ANVISA’s requirements, ensuring compliance and efficiency in the regulatory process.

What Changes with RDC 954/2024?

RDC 954/2024 seeks to optimize the regulation of medicines, making processes more agile and predictable. Some of the key changes include:

✅ Simplification of the documentation required for certain categories of medicines;
✅ More objective criteria for petitioning, reducing inconsistencies in submissions;
✅ Greater predictability in approval time, facilitating business planning.

For manufacturers and importers, understanding these changes is essential to ensure fast and secure registration.

QR Group: Your Strategic Partner in ANVISA Regulation

QR Group offers specialized solutions for companies looking for agility and security in the regularization of medicines in Brazil. Our team closely monitors all regulatory updates and assists in complying with the new requirements of RDC 954/2024.

🔹 Detailed interpretation of RDC 954/2024 and practical application in the registration of medicines;
🔹 Full support in ANVISA petitioning, avoiding delays and rework;
🔹 Strategies to optimize approval and reduce business impacts.

Ensure Compliance with QR Group

If your company needs to adapt to the new rules of RDC 954/2024, contact QR Group. Our expert team offers customized and agile solutions to ensure compliance and efficiency in drug registration.

Source: ANVISA